Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily LLY Bear 1X Shares

19.23
0.0000
Volume:- -
Turnover:- -
Market Cap:2.40M
PE:- -
High:19.23
Open:19.23
Low:19.23
Close:19.23
52wk High:25.04
52wk Low:16.40
Shares:125.00K
Float Shares:125.00K
Volume Ratio:- -
T/O Rate:- -
Dividend:1.01
Dividend Rate:5.26%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly - to Submit Biologics License Application for Retatrutide in Q1 2027

THOMSON REUTERS
·
Sep 30

Eli Lilly - 59.5% of Retatrutide 12 Mg Participants no Longer Meet Bmi Criteria for Obesity

THOMSON REUTERS
·
Sep 30

Eli Lilly Reports Zepbound Showed 4.5% Greater Weight Loss Than Novo Nordisk's Wegovy HD

MT Newswires Live
·
Sep 29

Eli Lilly’s Zepbound shows improved weight loss vs. Wegovy in new analysis

TIPRANKS
·
Sep 29

Eli Lilly - Zepbound 10 Mg and 15 Mg Show Comparable Adverse Event Discontinuation Rates to Wegovy Hd

THOMSON REUTERS
·
Sep 29

Eli Lilly - Zepbound 15 Mg Shows 4.5% Greater Weight Loss than Wegovy Hd in Adults with Obesity

THOMSON REUTERS
·
Sep 29

Lilly's Zepbound (Tirzepatide 10 Mg and 15 Mg) was Associated with More Weight Loss than Wegovy Hd (Semaglutide Injection 7.2 Mg) in a New Indirect Treatment Comparison

THOMSON REUTERS
·
Sep 29

Eli Lilly - Zepbound Achieves 20.2% Weight Reduction vs 13.7% for Wegovy at 72 Weeks

THOMSON REUTERS
·
Sep 29

Eli Lilly - Zepbound 15 Mg Users Have over Three Times the Odds of 20% Weight Reduction vs Wegovy Hd

THOMSON REUTERS
·
Sep 29

Lilly Touts Foundayo Advantage over Novo's Ozempic Pill in Diabetes Analysis

Reuters
·
Sep 29

Novo Nordisk Says Ozempic Shows Lower Risk of Cardiovascular Events Compared to Eli Lilly's Mounjaro

Reuters
·
Sep 29

Eli Lilly announces positive results from study of Foundayo 17.2 mg

TIPRANKS
·
Sep 29

Eli Lilly's Foundayo 17.2 Mg was Associated with 1.5% Greater Weight Loss at 52 Weeks

Reuters
·
Sep 29

Lilly Says Foundayo 17.2 Mg Outperforms Oral Semaglutide 25 Mg on Weight Loss, A1C in Indirect Comparison Study

Reuters
·
Sep 29

Eli Lilly - Foundayo 17.2 Mg Shows 1.5% Greater Weight Loss and 0.3% Greater A1c Reduction at 52 Weeks

THOMSON REUTERS
·
Sep 29

$20 Billion In Deals And Counting: Lilly's CEO Targets The "White Space" Of Science For Larger M&A

Options & Short Sell
·
Sep 29

DexCom’s Oura Bet: Potential Investment Gains Meet a Bigger Healthcare Opportunity

Bellwether Stocks Movement
·
Sep 29

AstraZeneca To Invest $2 Billion In Summit And Co-Develop Drugs; Shares Jump After Hours

Options & Short Sell
·
Sep 29

Sector Update: Healthcare

MT Newswires Live
·
Sep 29

Market Chatter: Eli Lilly CEO Plans Larger Deals to Target New Disease Areas

MT Newswires Live
·
Sep 29